Sellar Masses: An Epidemiological Study
- PMID: 26522017
- DOI: 10.1017/cjn.2015.301
Sellar Masses: An Epidemiological Study
Abstract
Background: Sellar masses (SM) are mostly benign growths of pituitary or nonpituitary origin that are increasingly encountered in clinical practice. To date, no comprehensive population-based study has reported the epidemiology of SM from North America.
Aim: To determine the epidemiology of SM in the province of Nova Scotia, Canada.
Methods: Data from all pituitary-related referrals within the province were prospectively collected in interlinked computerized registries starting in November 2005. We conducted a retrospective analysis on all patients with SM seen within the province between November 2005 and December 2013.
Results: A total of 1107 patients were identified, of which 1005 were alive and residing within the province. The mean age at presentation was 44.6±18 years, with an overall female preponderance (62%) and a population prevalence rate of 0.1%. Of patients with SM, 837 (83%) had pituitary adenomas and 168 (17%) had nonpituitary lesions. The relative prevalence and standardized incidence ratio, respectively, of various SM were: nonfunctioning adenomas (38.4%; 2.34), prolactinomas (34.3%; 2.22), Rathke's cyst (6.5%; 0.5), growth hormone-secreting adenomas (6.5%; 0.3), craniopharyngiomas (4.5%; 0.2), adrenocorticotropic hormone-secreting adenomas (3.8%; 0.2), meningiomas (1.9%), and others (3.9%; 0.21). At presentation, 526 (52.3%) had masses ≥1 cm, 318 (31.6%) at <1 cm, and 11 (1.1%) had functioning pituitary adenomas without discernible tumor, whereas tumor size data were unavailable in 150 (14.9%) patients. The specific pathologies and their most common presenting features were: nonfunctioning adenoma (incidental, headaches, and vision loss), prolactinomas (galactorrhea, menstrual irregularity, and headache), growth hormone-secreting adenomas (enlarging extremities and sweating), adrenocorticotropic hormone-secreting adenoma (easy bruising, muscle wasting, and weight gain) and nonpituitary lesions (incidental, headaches, and vision problems). Secondary hormonal deficiencies were common, ranging from 19.6% to 65.7%; secondary hypogonadism, hypothyroidism, and growth hormone deficiencies constituted the majority of these abnormalities.
Conclusions: This is the largest North American study to date to assess the epidemiology of SM in a large stable population. Given their significant prevalence in the general population, more studies are needed to evaluate the natural history of these masses and to help allocate appropriate resources for their management.
Keywords: pituitary adenomas; pituitary tumo.
Similar articles
-
Prevalence and characteristics of sellar masses in the city of Al Ain, United Arab Emirates: 2010 to 2016.Ann Saudi Med. 2020 Mar-Apr;40(2):105-112. doi: 10.5144/0256-4947.2020.105. Epub 2020 Apr 2. Ann Saudi Med. 2020. PMID: 32241168 Free PMC article.
-
Secondary pituitary hormonal dysfunction patterns: tumor size and subtype matter.Pituitary. 2020 Dec;23(6):622-629. doi: 10.1007/s11102-020-01067-7. Pituitary. 2020. PMID: 32715387
-
Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients.J Clin Endocrinol Metab. 2011 Jun;96(6):1633-41. doi: 10.1210/jc.2011-0168. Epub 2011 Apr 6. J Clin Endocrinol Metab. 2011. PMID: 21470998 Free PMC article.
-
Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas.Pituitary. 2018 Apr;21(2):111-118. doi: 10.1007/s11102-018-0869-3. Pituitary. 2018. PMID: 29368293 Review.
-
Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature.Neurosurg Focus. 2012 Jun;32(6):E2. doi: 10.3171/2012.4.FOCUS1268. Neurosurg Focus. 2012. PMID: 22655691 Review.
Cited by
-
TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice.Endocrinology. 2020 Aug 1;161(8):bqaa101. doi: 10.1210/endocr/bqaa101. Endocrinology. 2020. PMID: 32591776 Free PMC article.
-
Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.Neuro Oncol. 2022 Jul 1;24(7):1126-1139. doi: 10.1093/neuonc/noac050. Neuro Oncol. 2022. PMID: 35212383 Free PMC article.
-
Incidental versus symptomatic nonfunctioning pituitary adenomas: Are they different?Endocrinol Diabetes Metab. 2023 Nov;6(6):e445. doi: 10.1002/edm2.445. Epub 2023 Sep 11. Endocrinol Diabetes Metab. 2023. PMID: 37697708 Free PMC article.
-
Controlled Study of Pre- and Postoperative Headache in Patients with Sellar Masses (HEADs-uP Study).Endocrinol Diabetes Metab. 2024 Jul;7(4):e496. doi: 10.1002/edm2.496. Endocrinol Diabetes Metab. 2024. PMID: 39001600 Free PMC article.
-
A comparative, population-based analysis of pituitary incidentalomas vs clinically manifesting sellar masses.Endocr Connect. 2018 May;7(5):768-776. doi: 10.1530/EC-18-0065. Epub 2018 Apr 30. Endocr Connect. 2018. PMID: 29712721 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical